Skip to main content
. Author manuscript; available in PMC: 2021 Nov 18.
Published in final edited form as: Cell Syst. 2020 Oct 27;11(5):495–508.e10. doi: 10.1016/j.cels.2020.10.001

Figure 5. Adjuvant triplets generate potent cell-based vaccines against melanoma in mice.

Figure 5.

(A) Schematic overview of the experimental design. From left to right: mouse DCs are stimulated with adjuvant triplets and pulsed with ovalbumin (OVA) in vitro; then DCs are injected subcutaneously in mice which received 105 OVA-expressing B16.F10 melanoma cells (B16-OVA) in the contralateral skin region; and tumor growth is measured over time to assess vaccine effects.

(B) Average tumor growth (solid line) in cohorts of mice treated with DCs pulsed with OVA and stimulated with indicated adjuvant triplets (orange) or left unstimulated as control (black). Light color lines indicate the growth from each mouse within each cohort. Error bars, SEM (n = 3–15 mice per cohort).